Logo

Immunovant Provides an Update to Initiate P-III Trial of Batoclimab for the Treatment of Myasthenia Gravis

Share this
Immunovant Provides an Update to Initiate P-III Trial of Batoclimab for the Treatment of Myasthenia Gravis

Immunovant Provides an Update to Initiate P-III Trial of Batoclimab for the Treatment of Myasthenia Gravis

Shots:

  • The company will initiate the P-III trial to evaluate batoclimab (680/340mg) via weekly SC inj. in patients with MG. The company plans to start the trial in H1'22 & results are expected in 2024
  • The trial is designed to include an induction period. Additionally, primary efficacy analysis will be based on MG-ADL as measured in acetylcholine receptor Ab positive patients @12wks., follow-on treatment with alternative dosing regimens will be evaluated in subsequent study periods, safety is generally consistent with those used in other similar programs
  • Batoclimab is a fully human mAb targeting FcRn for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies

Ref: Globe Newswire | Image: Globe Newswire

Click here to­ read the full press release 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions